These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
403 related articles for article (PubMed ID: 31046743)
21. Entinostat in patients with relapsed or refractory abdominal neuroendocrine tumors. Jamison JK; Zhou M; Gelmann EP; Luk L; Bates SE; Califano A; Fojo T Oncologist; 2024 Sep; 29(9):817-e1213. PubMed ID: 38886159 [TBL] [Abstract][Full Text] [Related]
22. Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Luke JJ; Olson DJ; Allred JB; Strand CA; Bao R; Zha Y; Carll T; Labadie BW; Bastos BR; Butler MO; Hogg D; Munster PN; Schwartz GK Clin Cancer Res; 2020 Feb; 26(4):804-811. PubMed ID: 31558480 [TBL] [Abstract][Full Text] [Related]
23. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S; N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229 [TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial. Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714 [TBL] [Abstract][Full Text] [Related]
25. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. Carlino MS; Long GV; Schadendorf D; Robert C; Ribas A; Richtig E; Nyakas M; Caglevic C; Tarhini A; Blank C; Hoeller C; Bar-Sela G; Barrow C; Wolter P; Zhou H; Emancipator K; Jensen EH; Ebbinghaus S; Ibrahim N; Daud A Eur J Cancer; 2018 Sep; 101():236-243. PubMed ID: 30096704 [TBL] [Abstract][Full Text] [Related]
26. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Hauschild A; Trefzer U; Garbe C; Kaehler KC; Ugurel S; Kiecker F; Eigentler T; Krissel H; Schott A; Schadendorf D Melanoma Res; 2008 Aug; 18(4):274-8. PubMed ID: 18626312 [TBL] [Abstract][Full Text] [Related]
27. Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab. Johansson PA; Stark A; Palmer JM; Bigby K; Brooks K; Rolfe O; Pritchard AL; Whitehead K; Warrier S; Glasson W; Hayward NK Immunogenetics; 2019 May; 71(5-6):433-436. PubMed ID: 30714079 [TBL] [Abstract][Full Text] [Related]
28. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Pyrhönen S; Hahka-Kemppinen M; Muhonen T; Nikkanen V; Eskelin S; Summanen P; Tarkkanen A; Kivelä T Cancer; 2002 Dec; 95(11):2366-72. PubMed ID: 12436444 [TBL] [Abstract][Full Text] [Related]
29. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955 [TBL] [Abstract][Full Text] [Related]
30. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. Afzal MZ; Mabaera R; Shirai K J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557 [TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ; Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740 [TBL] [Abstract][Full Text] [Related]
33. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response. Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677 [TBL] [Abstract][Full Text] [Related]
34. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140 [TBL] [Abstract][Full Text] [Related]
35. The Role of Immune Checkpoint Blockade in Uveal Melanoma. Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269 [TBL] [Abstract][Full Text] [Related]
36. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Robert C; Ribas A; Wolchok JD; Hodi FS; Hamid O; Kefford R; Weber JS; Joshua AM; Hwu WJ; Gangadhar TC; Patnaik A; Dronca R; Zarour H; Joseph RW; Boasberg P; Chmielowski B; Mateus C; Postow MA; Gergich K; Elassaiss-Schaap J; Li XN; Iannone R; Ebbinghaus SW; Kang SP; Daud A Lancet; 2014 Sep; 384(9948):1109-17. PubMed ID: 25034862 [TBL] [Abstract][Full Text] [Related]
37. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963 [TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. Heppt MV; Steeb T; Schlager JG; Rosumeck S; Dressler C; Ruzicka T; Nast A; Berking C Cancer Treat Rev; 2017 Nov; 60():44-52. PubMed ID: 28881222 [TBL] [Abstract][Full Text] [Related]
39. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
40. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. Pili R; Salumbides B; Zhao M; Altiok S; Qian D; Zwiebel J; Carducci MA; Rudek MA Br J Cancer; 2012 Jan; 106(1):77-84. PubMed ID: 22134508 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]